Publications

Rosiglitazone Increased Heart failure But Did Not Differ from Metformin Plus Sulfonylurea for Other CV Outcomes at Interim Analysis

Journal Article

Authors
Mark A. Hlatky - Stanford University
Dena M. Bravata - Stanford University

Published by
American College of Physicians Journal Club, Vol. 147 no. 3, page(s) 67
November/December 2007

Download

Topics: United States

Publications of interest

Review: Rosiglitazone Increases Risk of MI But Does Not Differ from Other Drugs for CV Death in Type 2 Diabetes
Mark A. Hlatky, Dena M. Bravata
Evidence-Based Medicine vol. 12 (2007)
Guidelines for the Evaluation and Management of Heart Failure
JF Williams Jr, MR Bristow, MB Fowler, GS Francis, A Garson Jr, BJ Gersh, DF Hammer, Mark A. Hlatky, CV Leier, M Packer
J Am Coll Cardiol vol. 26 (1995)
Heart Failure Clinic, the: A Consensus Statement of the Heart Failure Society of America
Hauptman PJ, Rich MW, Paul A. Heidenreich, Chin J, Cummings N, Dunlap ME, Edwards ML, Gregory D, O'Commonr CM, Pezzella SM, Philibin E
Journal of Cardiac Failure vol. 14, 10 (2008)
Cardiac Resynchronization for Heart Failure
Mark A. Hlatky, BM Massie
Annals of Internal Medicine vol. 141, 5 (2004)